Author: [email protected]

Release – Nicola Mining Provides Update On Dominion Gold Project

Posted on by [email protected]

Research News and Market Data on HUSIF

November 4, 2025

News Releases

VANCOUVER, B.C., November 4, 2025 – Nicola Mining Inc. (TSX.V: NIM)(FSE: HLI) (OTCQB: HUSIF), (the “Company” or “Nicola”) is pleased to announce that it has completed work at Dominion for 2025 and has completed all mine development for the 10,000 bulk sample, which is planned to recommence in July of 2026.  Initially, the Company had planned to ship up to 2000 tonnes to the Nicola mill in 2025 for processing, but opted to wait until next year for two reasons:

Weather: Abnormally high rainfall during August and September would likely degrade the haul road from overuse. 

Project Size: During the mine development phase (“Development Phase”), which commenced in August following completion of haul road upgrades, a landing area (“Landing”) was constructed to provide access for vein extraction.  The Development Phase included lowering the entire Landing by approximately 6 metres to create a face suited for vein extraction.  While developing the Landing, three additional veins were discovered.

Dominion Map Higlighting 2025 Work and Vein Discoveries

Figure 1. Map showing the locations of 3 new veins discovered in 2025.
Note: The map is from 2020 due diligence with additional of veins uncovered in 2025 indicated.

Historically Known Veins:

  • South Pit Vein: Historically known vein from which previously chip samples were taken in 2020 Link.  Samples taken were comprised of two South Pit Samples and two 16 Vein Samples.  During 2025, the Company commenced vein extraction in the South Pit Zone, having moved the Landing down and working into the vein approximately 2 metres.  Approximately 20 metres from the entrance, the vein expands to approximately 5 metres in width.
  • 16 Vein: This historically known vein is located approximately 20 metres from the South Pit Vein. Chip samples and grab samples were taken from the vein during the October 14, 2020 due diligence process.

Newly Exposed Veins:

  • Mid-West Vein: Located 13 metres from the South Pit Vein.  The vein is approximately 1 metre wide and exposed over 3 metres.
  • West Vein: Located 12 metres from the Mid-West Vein. The vein is approximately 3 metres wide and exposed over 6 metres.
  • 16 East Vein: Located 1.5-2 metres east of the 16 Vein. It is approximately 1.5 metres wide and exposed over 40 metres.

Samples from the newly exposed veins were taken by site crew and brought to Paragon Geochemical for analysis. Paragon Geochemical is an ISO 17025:2017 accredited geochemical testing laboratory providing analytical services to the mining industry.  Results will be released upon receipt.

Figure 6. Mid-West Vein

Mr. Peter Espig, CEO of Nicola Mining Inc., commented, “We have been pleasantly surprised with the work at Dominion, which clearly indicates that the project is larger than initially anticipated.  For the 2026 Program, we now have 5 open faces that are accessible from the Landing to give approximately 6 metres of strike length for extraction. These exposed veins also represent attractive exploration targets as they are open at depth.”

Qualified Person

The scientific and technical disclosures included in this news release have been reviewed and approved by Will Whitty, P.Geo., who is the Qualified Person as defined by NI 43-101. Mr. Whitty is Vice President of Exploration for the Company.

DOMINION CREEK PROPERTY HISTORY

The Dominion Creek Property consists of 9 mineral claims (55 units) totaling approximately 1,058 hectares. The property was acquired from the prospector N. Kencayd by Noranda Exploration Company Ltd. in 1986. Noranda subsequently conducted geological, geochemical, and geophysical surveys which culminated in an increase in their land position. Between 1987 and 1990, Noranda’s exploration program included a small (20 samples) geochemical silt sample survey. Encouraged by those results, a larger soil geochemical survey (3,399 samples) was conducted. Noranda drilled a total of 53 shallow diamond drill holes, totaling 3,483.86 meters (average depth of approximately 65.7 meters). Trenching of several coincident Pb, Zn, Cu, Ag and Au soil geochemistry anomalies resulted in the discovery of several mineralized quartz veins.

Drilling in the South Zone covered an area of approximately 300 meters by 200 meters. Limited drilling in the North Zone covered two small areas (approximately 50 meters by 60 meters) 300 meters apart. The drill targets were selected using the soil geochemistry survey data and outcrop sampling from trenches and the drill access road data. Noranda subsequently returned the property to N. Kencayd, who sold it to A. Raven in 1989.

A Technical Report[1] on the Dominion Creek Project was completed by Geospectrum Engineering on August 22, 2003.

About Nicola Mining

Nicola Mining Inc. is a junior mining company listed on the Exchange and Frankfurt Exchange that maintains a 100% owned mill and tailings facility, located near Merritt, British Columbia. It has signed Mining and Milling Profit Share Agreements with high grade gold projects. Nicola’s fully permitted mill can process both gold and silver mill feed via gravity and flotation processes.

The Company owns 100% of the New Craigmont Project, a high-grade copper property, which covers an area of 10,913 hectares along the southern end of the Guichon Batholith and is adjacent to Highland Valley Copper, Canada’s largest copper mine. The Company also owns 100% of the Treasure Mountain Property, which includes 30 mineral claims and a mineral lease, spanning an area exceeding 2,200 hectares.

On behalf of the Board of Directors

“Peter Espig”
Peter Espig
CEO & Director

For additional information

Contact: Peter Espig
Phone: (778) 385-1213
Email: [email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

[1] Makepeace, D. K., 2003. Dominion Creek Project Technical Report for XMP Mining Ltd. Geospectrum Engineering, August 22.

Share:

Nicola Mining Announces Plans To Uplist On Nasdaq And Filing Of Short Form Base Shelf Prospectus

The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, Nicola Mining Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

Release – Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

Posted on by [email protected]

Research News and Market Data on TNXP

November 04, 2025 7:00am EST Download as PDF

Planning to initiate an open-label Phase 2 study of TNX-1500 under an investigator-initiated IND to evaluate safety and activity in the first half of 2026  

Novel immunomodulatory regimen designed to reduce calcineurin inhibitor exposure and improve outcomes

Dimeric Fc-modified mAb TNX-1500 selectively targets cell-associated CD40L with once-monthly dosing

CHATHAM, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated, commercial biotechnology company, today announced a collaboration with Massachusetts General Hospital (MGH), a founding member of Mass General Brigham (MGB) to conduct a Phase 2 clinical trial evaluating monoclonal antibody (mAb) TNX-1500 in kidney transplant recipients. The investigator-initiated study will be led by Ayman Al Jurdi, M.D., at MGH and is designed to assess the safety, tolerability and activity of Fc-modified anti-CD40L mAb TNX-1500 in preventing kidney transplant rejection while significantly minimizing the dose of conventional immunosuppressive drugs, which are associated with infection, cancer, cardiovascular side effects and various metabolic derangements. The CD40 ligand (CD40L) is also known as CD154. Study initiation is contingent on institutional review board (IRB) approval and FDA clearance of an investigator-initiated investigational new drug application (IND).

“TNX-1500 represents a differentiated approach that is designed to block the function of cell-associated CD40L,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “Collaborating with MGH, one of the nation’s leading transplant research centers, allows us to advance this promising candidate in patients who need safer therapies with better long-term outcomes. The Fc-modified TNX-1500 has shown activity and has been well tolerated in animals1,2 and in a Phase 1 pharmacodynamic (PD) and pharmacokinetic (PK) study that supports monthly dosing. Ultimately, our goal is to establish TNX-1500 as a monotherapy, with the potential to transform the landscape of organ transplant management.”

“The ability to modulate the immune system without the toxicities associated with prolonged standard dose CNIs is one of the most pressing unmet needs in transplantation,” said Ayman Al Jurdi, M.D., Principal Investigator at MGH. “Studying TNX-1500 in this Phase II trial will allow us to explore its potential to improve long-term outcomes for kidney transplant recipients.”

Pending IRB approval and IND clearance, the open-label, single-center study will enroll five adult kidney transplant recipients at MGH. Patients will receive induction therapy with anti-thymocyte globulin, TNX-1500, tacrolimus, and corticosteroids. The corticosteroids will be tapered and discontinued by Day 33 post-transplant. TNX-1500 will be continued for 12 months (to the primary endpoint) with an option to continue treatment beyond 12 months. Tacrolimus at standard dose will be continued for six months, at which point tacrolimus will be decreased to low dose with the expectation of discontinuing tacrolimus after 12 months. The primary endpoint is the incidence of adverse and serious adverse events at 12 months. Secondary endpoints include graft survival, renal function, biopsy-proven acute rejection, and incidence of donor-specific antibodies. The study is expected to be initiated in the first half of 2026.

About TNX-1500

TNX-1500 (Fc-modified humanized anti-CD40L mAb) is a humanized monoclonal antibody that interacts with the CD40-ligand (CD40L), also known as CD154. TNX-1500 is being developed for the prevention of allograft and xenograft rejection, for the prevention of graft-versus-host disease (GvHD) after hematopoietic stem cell transplantation (HCT) and for the treatment of autoimmune diseases. The first-in-human Phase 1 PD/PK study of TNX-1500 was completed and topline reported in first quarter 2025 to support dosing in a planned Phase 2 trial in kidney transplant recipients. The primary objective of the Phase 1 trial was to assess the safety, tolerability, PD and PK of single-dose intravenous (i.v.) TNX-1500 at 3 mg/kg, 10 mg/kg, and 30 mg/kg. Two published articles in the peer-reviewed American Journal of Transplantation demonstrate TNX-1500 prevents rejection, prolongs survival and preserves graft function as a single agent or in combination with other drugs in animal renal and heart allografts.1,2

1Lassiter G, et al. Am J Transplant. 2023;23(8):1171-1181.
2Miura S, et al. Am J Transplant. 2023;23(8):1182-1193.

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals is a fully-integrated commercial biotechnology company with marketed products and a pipeline of development candidates. Tonix has received FDA approval for Tonmya™ (cyclobenzaprine HCl sublingual tablets), a first-in-class, non-opioid analgesic medicine for the treatment of fibromyalgia, a chronic pain condition that affects millions of adults. This marks the first approval for a new prescription medicine for fibromyalgia in more than 15 years. Tonix also markets two treatments for acute migraine in adults. Tonix’s development portfolio is focused on central nervous system (CNS) disorders, immunology, immuno-oncology, rare disease and infectious disease. TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). TNX-102 SL is also in development for major depressive disorder. Tonix’s rare disease portfolio includes TNX-2900, intranasal potentiated oxytocin with magnesium, in development for Prader-Willi syndrome. Tonix’s infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, as well as TNX-4800, a monoclonal antibody for the seasonal prevention of Lyme Disease. Finally, TNX-4200 for which Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years, is a small molecule broad-spectrum antiviral agent targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md.

* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize Tonmya and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Jessica Morris 
Tonix Pharmaceuticals 
[email protected] 
(862) 799-8599 

Brian Korb 
astr partners 
(917) 653-5122 
[email protected] 

Media Contact 
Mary Ann Ondish
Tonix Pharmaceuticals 
[email protected] 
(862) 799-8599 

Ray Jordan 
Putnam Insights 
[email protected] 
 
INDICATION
TONMYA is indicated for the treatment of fibromyalgia in adults.
CONTRAINDICATIONS
TONMYA is contraindicated:
In patients with hypersensitivity to cyclobenzaprine or any inactive ingredient in TONMYA. Hypersensitivity reactions may manifest as an anaphylactic reaction, urticaria, facial and/or tongue swelling, or pruritus. Discontinue TONMYA if a hypersensitivity reaction is suspected.
With concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after discontinuation of an MAO inhibitor. Hyperpyretic crisis seizures and deaths have occurred in patients who received cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitors drugs.
During the acute recovery phase of myocardial infarction, and in patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.
In patients with hyperthyroidism.
WARNINGS AND PRECAUTIONS
Embryofetal toxicity: Based on animal data, TONMYA may cause neural tube defects when used two weeks prior to conception and during the first trimester of pregnancy. Advise females of reproductive potential of the potential risk and to use effective contraception during treatment and for two weeks after the final dose. Perform a pregnancy test prior to initiation of treatment with TONMYA to exclude use of TONMYA during the first trimester of pregnancy.
Serotonin syndrome: Concomitant use of TONMYA with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors increases the risk of serotonin syndrome, a potentially life-threatening condition. Serotonin syndrome symptoms may include mental status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms. Treatment with TONMYA and any concomitant serotonergic agent should be discontinued immediately if serotonin syndrome symptoms occur and supportive symptomatic treatment should be initiated. If concomitant treatment with TONMYA and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dosage increases.
Tricyclic antidepressant-like adverse reactions: Cyclobenzaprine is structurally related to TCAs. TCAs have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke. If clinically significant central nervous system (CNS) symptoms develop, consider discontinuation of TONMYA. Caution should be used when TCAs are given to patients with a history of seizure disorder, because TCAs may lower the seizure threshold. Patients with a history of seizures should be monitored during TCA use to identify recurrence of seizures or an increase in the frequency of seizures.
Atropine-like effects: Use with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic drugs.
CNS depression and risk of operating a motor vehicle or hazardous machinery: TONMYA monotherapy may cause CNS depression. Concomitant use of TONMYA with alcohol, barbiturates, or other CNS depressants may increase the risk of CNS depression. Advise patients not to operate a motor vehicle or dangerous machinery until they are reasonably certain that TONMYA therapy will not adversely affect their ability to engage in such activities.
Oral mucosal adverse reactions: In clinical studies with TONMYA, oral mucosal adverse reactions occurred more frequently in patients treated with TONMYA compared to placebo. Advise patients to moisten the mouth with sips of water before administration of TONMYA to reduce the risk of oral sensory changes (hypoesthesia). Consider discontinuation of TONMYA if severe reactions occur.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at a higher incidence in TONMYA-treated patients compared to placebo-treated patients) were oral hypoesthesia, oral discomfort, abnormal product taste, somnolence, oral paresthesia, oral pain, fatigue, dry mouth, and aphthous ulcer.
DRUG INTERACTIONS
MAO inhibitors: Life-threatening interactions may occur.
Other serotonergic drugs: Serotonin syndrome has been reported.
CNS depressants: CNS depressant effects of alcohol, barbiturates, and other CNS depressants may be enhanced.
Tramadol: Seizure risk may be enhanced.
Guanethidine or other similar acting drugs: The antihypertensive action of these drugs may be blocked.
USE IN SPECIFIC POPULATIONS
Pregnancy: Based on animal data, TONMYA may cause fetal harm when administered to a pregnant woman. The limited amount of available observational data on oral cyclobenzaprine use in pregnancy is of insufficient quality to inform a TONMYA-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pregnant women about the potential risk to the fetus with maternal exposure to TONMYA and to avoid use of TONMYA two weeks prior to conception and through the first trimester of pregnancy. Report pregnancies to the Tonix Medicines, Inc., adverse-event reporting line at 1-888-869-7633 (1-888-TNXPMED).
Lactation: A small number of published cases report the transfer of cyclobenzaprine into human milk in low amounts, but these data cannot be confirmed. There are no data on the effects of cyclobenzaprine on a breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TONMYA and any potential adverse effects on the breastfed child from TONMYA or from the underlying maternal condition.
Pediatric use: The safety and effectiveness of TONMYA have not been established.
Geriatric patients: Of the total number of TONMYA-treated patients in the clinical trials in adult patients with fibromyalgia, none were 65 years of age and older. Clinical trials of TONMYA did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.
Hepatic impairment: The recommended dosage of TONMYA in patients with mild hepatic impairment (HI) (Child Pugh A) is 2.8 mg once daily at bedtime, lower than the recommended dosage in patients with normal hepatic function. The use of TONMYA is not recommended in patients with moderate HI (Child Pugh B) or severe HI (Child Pugh C). Cyclobenzaprine exposure (AUC) was increased in patients with mild HI and moderate HI compared to subjects with normal hepatic function, which may increase the risk of TONMYA-associated adverse reactions.
Please see additional safety information in the full Prescribing Information.
To report suspected adverse reactions, contact Tonix Medicines, Inc. at 1-888-869-7633, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Primary Logo

Source: Tonix Pharmaceuticals Holding Corp.

Released November 4, 2025

Release – GeoVax Announces Relocation of Corporate Headquarters and Laboratory Operations to Support Accelerated Growth and Pipeline Advancement

Posted on by [email protected]

Research News and Market Data on GOVX

Relocations Strengthen Ties to Georgia’s Bio-Ecosystem and Position GeoVax for Late-Stage Development and Market Readiness

Atlanta, GA – November 3, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and multi-antigen vaccines against cancers and infectious diseases, today announced relocations of its corporate headquarters and laboratory operations to new facilities in the Atlanta metropolitan area. The moves, scheduled for fourth quarter of 2025, will support GeoVax’s continued growth, expanding pipeline, and preparation for product commercialization.

GeoVax’s laboratory group is relocating to Science Square / Portal Innovations, located in midtown Atlanta. This state-of-the-art facility will provide the Company’s R&D team with expanded access to modern laboratories and collaborative research environments designed to accelerate innovation and development activities.

The Company’s new corporate headquarters will be located at 1955 Lake Park Drive in Smyrna, Georgia, establishing a new hub for corporate operations and leadership activities.

“These moves reflect a significant milestone in GeoVax’s evolution,” said David Dodd, Chairman and Chief Executive Officer of GeoVax. “By placing members of our R&D team in one of the most dynamic bio-research ecosystems in the Southeast, and by expanding our administrative base, we are positioning GeoVax for an accelerated next stage of growth. These facilities will support our broad and advancing pipeline, which includes our promising GEO-MVA program and multiple clinical trials in cancer therapy and infectious disease vaccines.”

“We are incredibly excited for GeoVax to join Portal Atlanta at Science Square Labs,” said Eddie Lai, Director of Business Development, Atlanta Portal Innovations. “GeoVax brings a strong legacy of innovation rooted in the Southeast to the Portal Innovations ecosystem that includes 100+ innovative companies utilizing our sites across the country. As an innovation engine, Portal Innovations supports scientific companies including life sciences and biotech in all stages of development in both R&D and administrative capabilities, and GeoVax is a perfect addition to our growth right here in Atlanta.”

The relocations underscore GeoVax’s trajectory as a company focused on long-term growth, scientific advancement, and future commercialization opportunities. As the Company builds momentum with a deepening pipeline and strategic partnerships, its enhanced infrastructure will provide a strong foundation to meet global healthcare needs.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:

[email protected]

678-384-7220

Media Contact:

Jessica Starman

[email protected] 

Release – NeuroSense to Host Investor Webinar on December 8, 2025

Posted on by [email protected]

Research News and Market Data on NRSN

Business, regulatory and clinical updates will be provided

CAMBRIDGE, Mass., Nov. 3, 2025 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that it will host an investor update meeting on December 8, 2025 at 8:30 a.m. Eastern Time.

The Company plans to provide status updates about its near-term milestones and objectives:

  1. Phase 3 PARAGON study initiation (ALS)
  2. Notice of Compliance with conditions (NOC/c) submission in Canada
  3. Status of the binding term sheet executed in December 2024
  4. RoAD Phase 2 program (Alzheimer’s disease)

Investors interested in attending the webinar are invited to register here.

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of regulatory filings, meetings and regulatory decisions. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 7, 2025 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

SOURCE NeuroSense

Release – The Beachbody Company, Inc. Announces Third Quarter 2025 Earnings Release Date, Conference Call, and Webcast

Posted on by [email protected]

Research News and Market Data on BODI

November 3, 2025

    EL SEGUNDO, Calif.–(BUSINESS WIRE)– The Beachbody Company, Inc. (NASDAQ: BODI) (“BODi” or the “Company”), a leading fitness and nutrition company, will release its third quarter 2025 results on Monday, November 10, 2025, after the U.S. stock market closes. The Company will host a conference call at 5:00 p.m. (Eastern Time) that day to discuss the results.

    The toll-free dial-in for the conference call is (833) 470-1428 (U.S. & Canada), or click here for Global Dial-In Numbers. The conference ID is 828838. A live webcast of the conference call will also be available on the Company’s investor relations website at https://investors.thebeachbodycompany.com/.

    For those unable to participate in the conference call, a replay will be available after the conclusion of the call on November 10, 2025, through November 17, 2025. The toll-free replay dial-in number is (866) 813-9403 (U.S & Canada). The replay passcode is 739586.

    About BODi and The Beachbody Company, Inc.

    Originally known as Beachbody, BODi has been innovating structured step-by-step home fitness and nutrition programs for 26 years with products such as P90X, Insanity, and 21-Day Fix, plus the first premium superfood nutrition supplement, Shakeology. Since its inception in 1999, BODi has helped over 30 million customers pursue extraordinary life-changing results. The BODi community includes millions of people helping each other stay accountable to goals of healthy weight loss, improved strength and energy, and resilient mental and physical well-being. For more information, please visit thebeachbodycompany.com.

    Investor Relations
    [email protected]

    Source: The Beachbody Company, Inc.

    Release – InPlay Oil Corp. Confirms Monthly Dividend for November 2025

    Posted on by [email protected]
    InPlay Oil logo (CNW Group/InPlay Oil Corp.)

    Research News and Market Data on IPOOF

    CALGARY, AB, Nov. 3, 2025 /CNW/ – InPlay Oil Corp. (TSX: IPO) (OTCQX: IPOOF) (“InPlay” or the “Company”) is pleased to confirm that its Board of Directors has declared a monthly cash dividend of $0.09 per common share payable on November 28, 2025, to shareholders of record at the close of business on November 14, 2025.  The monthly cash dividend is expected to be designated as an “eligible dividend” for Canadian federal and provincial income tax purposes.

    About InPlay Oil Corp.

    InPlay is a junior oil and gas exploration and production company with operations in Alberta focused on light oil production. The company operates long-lived, low-decline properties with drilling development and enhanced oil recovery potential as well as undeveloped lands with exploration possibilities. The common shares of InPlay trade on the Toronto Stock Exchange under the symbol IPO and the OTCQX Exchange under the symbol IPOOF.

    SOURCE InPlay Oil Corp.

    For further information please contact: Doug Bartole, President and Chief Executive Officer, InPlay Oil Corp., Telephone: (587) 955-0632, www.inplayoil.com; Darren Dittmer, Chief Financial Officer, InPlay Oil Corp., Telephone: (587) 955-0634

    Release – Kratos Announces the GEK800 Has Successfully Completed Altitude Testing

    Posted on by [email protected]

    Research News and Market Data on KTOS

    October 31, 2025

    PDF Version Engine Designed for Next-Gen CCA-type Aircraft

    SAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a technology company in Defense, National Security and Global Markets, and GE Aerospace (NYSE:GE) today announced the successful completion of altitude testing. The companies also conducted durability and limits testing on its GEK800 engine designed to power the next generation of affordable unmanned aerial systems and CCA-type aircraft. The testing began late September and progressed through a very stringent timeline through altitude tests and concluded this week with testing engine limits.

    “Successfully completing altitude testing marks a major milestone in the GEK800 engine program and demonstrates the strength of our partnership with GE Aerospace, AFRL, and Purdue University’s Zucrow Laboratories,” said Stacey Rock, President of Kratos Turbine Technologies. “This collaboration has been instrumental in advancing the engine’s development, validating its performance, and accelerating its path toward production. Together, we’re delivering on our shared commitment to provide high-performance, affordable propulsion systems that can be rapidly produced to meet the demands of our defense customers.”

    With the successful completion of altitude testing, the test team – a collaboration between Kratos, GE Aerospace, and Purdue University’s Maurice J. Zucrow Laboratories – has achieved a major milestone this week, pushing boundaries which demonstrate the robustness of this advanced engine design and gaining a clear path towards production in delivering on our nation’s defense readiness with the aid of rapid and affordable testing. This engine test also marks the first at the newly expanded ZL9 test facility at Zucrow Labs.

    “Our joint team successfully expanded the altitude testing envelope and identified the engine’s rotor speed limits and compressive system boundaries. This testing further demonstrated the engine’s outstanding performance and durability,” said Mark Rettig, Vice President & General Manager of Edison Works Business & Technology Development at GE Aerospace. 

    StallTesting1 Induced Stall Testing Exhaust Flame Durability and Limits Test

    A photo accompanying this announcement is available at
    https://www.globenewswire.com/NewsRoom/AttachmentNg/207fc807-7669-459d-aabf-5271c30e4880

    The GEK800 is an 800-lb jet engine that could potentially power unmanned aerial systems (UAS), collaborative combat aircraft (CCAs), and missiles. Initially developed and ground tested by Kratos over the course of a decade, Kratos and GE Aerospace began working together in 2023 to complete additional development efforts and testing on the engine and have completed more than 50 engine starts in ground testing at Kratos and GE Aerospace testing facilities. In a collaboration with GE Aerospace, Kratos Defense, and Purdue Zucrow Labs, an aggressive test timeline was met and successfully demonstrated a reliable, durable engine solution. Success in testing has been made possible with the involvement of both the Air Force Research Laboratory (AFRL) and Office of Naval Research (ONR).

    “The recent collaboration between GE Aerospace, Purdue University, and the Kratos test teams demonstrated a high level of alignment, efficiency, and technical excellence. The joint team successfully met nearly all test objectives while also validating the capability to conduct this style of testing within a newly commissioned facility. The dedication, expertise, and hard work contributed by each team member were instrumental to the success of this effort and are truly commendable,” said Daniel Fineberg, Kratos GEK800 Test Coordination Lead.

    In June, Kratos and GE Aerospace announced the signing of a formal teaming agreement to advance propulsion technologies for the next generation of affordable unmanned aerial systems and CCA-type aircraft. This collaboration strengthens the companies’ ongoing partnership and builds on last year’s Memorandum of Understanding (MOU) to advance the development and production of small, cost-effective engines for unmanned platforms. The new teaming agreement expands on that MOU and provides the framework for the two companies to develop, manufacture, test, and field the GEK800 engine.

    Kratos brings more than 25 years of experience developing and producing small, affordable engines for UAS, drones, and missile platforms. GE Aerospace adds a century of expertise in propulsion technology and the ability to scale advanced designs into high-rate production, helping bridge the gap from prototype to deployment.

    About Kratos Defense & Security Solutions
    Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com.

    Notice Regarding Forward-Looking Statements
    Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 29, 2024, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

    About GE Aerospace   
    GE Aerospace is a global aerospace propulsion, services, and systems leader with an installed base of approximately 49,000 commercial and 29,000 military aircraft engines. With a global team of approximately 53,000 employees building on more than a century of innovation and learning, GE Aerospace is committed to inventing the future of flight, lifting people up, and bringing them home safely. Learn more about how GE Aerospace and its partners are defining flight for today, tomorrow, and the future at www.geaerospace.com. 

    Press Contact:
    Claire Cantrell
    [email protected]

    Investor Information:
    877-934-4687
    [email protected]

    Primary Logo
    Induced Stall Testing Exhaust Flame Durability and Limits Test

     

    Induced Stall Testing Exhaust Flame Durability and Limits Test

    Source: Kratos Defense & Security Solutions, Inc.

    Release – Conduent Appoints Michael J. Fucci to Board of Directors

    Posted on by [email protected]

    Research News and Market Data on CNDT

    October 31, 2025

    Corporate

    Respected Business Leader and Former Deloitte US Chair Brings Decades of Strategic and Operational Experience

    FLORHAM PARK, N.J. — Conduent Incorporated (Nasdaq: CNDT), a global technology-driven business solutions and services company, today announced the appointment of Michael J. Fucci to its Board of Directors, effective October 27.

    Mr. Fucci brings more than 40 years of leadership experience, having most recently served as Deloitte US Chair from 2015-2019. In that role, he provided governance and strategic oversight on key priorities including enterprise strategy, leadership succession, risk management, talent development, and executive compensation driving both revenue growth and market share. He joined Deloitte’s board of directors in 2012 and currently serves on the board of directors of Acadia Healthcare and Flotek Industries, Inc.

    Beginning his career with Deloitte’s predecessor firm in 1981, Mr. Fucci played a pivotal role in expanding the firm’s human capital business into an industry leader and later served as Chief Operating Officer. He retired from Deloitte in 2020.

    “I’m pleased to welcome Mike to Conduent’s Board of Directors,” said Cliff Skelton, President and CEO of Conduent. “He is a highly respected global leader whose deep business acumen and strategic insight will be invaluable as we continue to execute our growth strategy and deliver value to our shareholders, clients and associates.”

    “I’m excited to join Conduent’s Board at such a promising time for the company,” said Fucci. “The progress made over the past several years has laid a strong foundation for future growth. I look forward to working with Conduent’s Board and leadership team to help sustain and accelerate that momentum.”

    Conduent Chairman Harsha V. Agadi stated: “Welcoming a director of Mike Fucci’s caliber and integrity is a significant gain for Conduent. His leadership perspective and deep experience in professional services will serve all of our stakeholders well.”

    About Conduent

    Conduent delivers digital business solutions and services spanning the commercial, government and transportation spectrum – creating valuable outcomes for its clients and the millions of people who count on them. The Company leverages cloud computing, artificial intelligence, machine learning, automation and advanced analytics to deliver mission-critical solutions. Through a dedicated global team of approximately 56,000 associates, process expertise and advanced technologies, Conduent’s solutions and services digitally transform its clients’ operations to enhance customer experiences, improve performance, increase efficiencies and reduce costs. Conduent adds momentum to its clients’ missions in many ways including disbursing approximately $85 billion in government payments annually, enabling 2.3 billion customer service interactions annually, empowering millions of employees through HR services every year and processing nearly 13 million tolling transactions every day. Learn more at www.conduent.com.

    Forward-Looking Statements

    This press release, any exhibits or attachments to this release, and other public statements we make may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “estimate,” “expect,” “expectations,” “in front of us,” “plan,” “intend,” “will,” “aim,” “should,” “could,” “forecast,” “target,” “may,” “continue,” “look forward”, and similar expressions (including the negative and plural forms of such words and phrases), as they relate to us, are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. All statements other than statements of historical fact included in this press release or any attachment to this press release are forward-looking statements. These statements reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions, many of which are outside of our control, that could cause actual results to differ materially from those expected or implied by such forward-looking statements contained in this press release, any exhibits to this press release and other public statements we make. Important factors and uncertainties that could cause our actual results to differ materially from those in our forward-looking statements include, but are not limited to those factors that are set forth in our 2024 Annual Report on Form 10-K, as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with or furnished to the Securities and Exchange Commission. Any forward-looking statements made by us in this release speak only as of the date on which they are made. We are under no obligation to, and expressly disclaim any obligation to, update or alter our forward-looking statements, whether because of new information, subsequent events or otherwise, except as required by law.

    Note: To receive RSS news feeds, visit www.news.conduent.com. For open commentary, industry perspectives and views, visit http://twitter.com/Conduent, http://www.linkedin.com/company/conduent or http://www.facebook.com/Conduent.

    Trademarks

    Conduent is a trademark of Conduent Incorporated in the United States and/or other countries. Other names may be trademarks of their respective owners.

    Media Contacts

    Sean Collins

    Conduent

    [email protected]

    +1-310-497-9205

    Josh Overholt

    Conduent

    [email protected]

    Release – ACCO Brands Reports Third Quarter Results

    Posted on by [email protected]

    Research News and Market Data on ACCO

    10/30/2025

    • Reported net sales of $384 million
    • Gross margin expanded; SG&A down compared to prior year
    • Multi-year cost reduction program has yielded more than $50 million of savings
    • Earnings per share of $0.04, adjusted earnings per share of $0.21, in line with the Company’s outlook

    LAKE ZURICH, Ill.–(BUSINESS WIRE)– ACCO Brands Corporation (NYSE: ACCO) today reported financial results for its third quarter and nine-months ended September 30, 2025.

    “We delivered third quarter adjusted EPS in line with our outlook and expanded gross margin by 50 basis points as we continue to demonstrate strong operational discipline through continued execution of our $100 million cost reduction program. Sales were lower than expected in the quarter, as the demand environment for many of our categories remained soft globally. We expect sales trends to improve in the fourth quarter, reflecting the favorable impact of foreign exchange and growth in the technology accessories categories,” stated ACCO Brands’ President and Chief Executive Officer, Tom Tedford.

    “We are confident in our ability to deliver future value creation for our shareholders. Our teams continue to execute on our cost management initiatives, while remaining focused on enhancing our revenue opportunities. Innovation is core to our strategy; the fourth quarter new product launches will help abate the secular headwinds, while we also evaluate strategic opportunities that align with our growth objectives. We believe our leading brands, combined with our optimized operational structure, give us a strong platform for growth,” concluded Mr. Tedford.

    Third Quarter Results

    Net sales were $383.7 million, down 8.8 percent from $420.9 million in 2024. Favorable foreign exchange increased sales by $6.5 million, or 1.5 percent. Comparable sales decreased 10.3 percent. The decline in net sales reflects softer global demand for our products.

    Operating income was $26.0 million, versus $26.3 million in 2024. Restructuring expense was $1.5 million, compared to $6.7 million in the prior year. Adjusted operating income was $39.2 million, compared to $44.7 million in 2024. The decline in adjusted operating income reflects lower sales volume, lower fixed-cost absorption, and tariff-related impacts, which were partially offset by cost savings and lower incentive compensation expense.

    Net income was $4.0 million, or $0.04 per share, compared with prior-year net income of $9.3 million, or $0.09 per share. The decline in net income reflects items noted above in operating income, as well as discrete tax items and other expense of $5.5 million, compared to $0.2 million of a reversal in the prior year. Adjusted net income was $19.5 million, compared with adjusted net income of $22.5 million in 2024, and adjusted earnings per share were $0.21, compared with $0.23 in 2024.

    Business Segment Results

    ACCO Brands Americas – Third quarter segment net sales of $227.6 million decreased 12.2 percent from $259.1 million in the prior year. Net sales in the quarter were negatively impacted by softer demand for our product categories, partly offset by price increases.

    Third quarter operating income was $24.7 million, compared to $25.9 million a year earlier. Restructuring expense associated with the multi-year cost reduction program was $0.6 million, compared to $3.4 million in the prior year. Adjusted operating income was $32.7 million, down from $36.7 million in the prior year. The decrease in adjusted operating income reflects lower sales volume, lower fixed-cost absorption and impacts from tariffs, partially offset by cost savings and price.

    ACCO Brands International – Third quarter segment net sales of $156.1 million decreased 3.5 percent from $161.8 million in the prior year. Favorable foreign exchange increased sales by 3.8 percent. Comparable sales were $150.0 million, down 7.3 percent versus the prior year. Comparable sales declines reflect reduced demand for our product categories, partially offset by the benefit of price increases and the acquisition of Buro Seating.

    Third quarter operating income was $10.5 million, compared to $9.5 million in the prior year. Restructuring expense associated with the multi-year cost reduction program of $1.1 million, compared to $3.3 million in the prior year. Adjusted operating income was $15.9 million, compared with $17.1 million in the prior year. The decrease in adjusted operating income reflects the impact of lower sales volume, partially offset by pricing actions and cost savings.

    Nine Month Results

    Net sales were $1,095.9 million, down 10.0 percent from $1,218.1 million in 2024. Net sales declines reflect the impact from softer global demand and tariff-related impacts.

    Operating income was $52.3 million, versus an operating loss of $79.0 million in 2024, primarily due to non-cash impairment charges of $165.2 million related to goodwill and intangible assets within the Americas segment in the prior year. Restructuring expense of $13.2 million, compared to $6.1 million in the prior year. Current year operating income benefited from a gain on sale of assets of $6.9 million. Adjusted operating income was $93.2 million, down from $125.5 million in 2024. Adjusted operating income decline reflects lower sales volume and tariff related impacts, which were partially offset by cost savings and lower incentive compensation expense.

    Net income was $20.0 million, or $0.21 per share, compared with a net loss of $122.2 million, or $(1.27) per share, in 2024. Net income in the nine-month period was positively impacted by the same items noted above in operating income. Current year net income was also positively impacted by the settlement of outstanding tax assessments in Brazil, resulting in a benefit of $13.1 million. The prior year loss reflects the items noted above in operating income. Adjusted net income was $43.3 million, compared with $61.7 million in 2024, and adjusted earnings per share were $0.46 per share, compared with $0.63 per share in 2024.

    Capital Allocation and Dividend

    Year to date, operating cash flow was $38.1 million versus $95.5 million in the prior year. Adjusted free cash flow of $42.3 million compared to $86.9 million in the prior year. The Company’s consolidated leverage ratio as of September 30, 2025 was 4.1x.

    Year to date, the Company has paid dividends of $20.3 million. In the first quarter, the Company repurchased 3.2 million shares of common stock for $15.1 million.

    On October 24, 2025, ACCO Brands announced that its board of directors declared a regular quarterly cash dividend of $0.075 per share. The dividend will be paid on December 10, 2025 to stockholders of record at the close of business on November 21, 2025.

    Reaffirming Full Year 2025 Outlook

    For the full year, the Company expects reported sales to be down in the range of 7.0% to 8.5%. Full year adjusted EPS is expected to be within the range of $0.83 to $0.90. The Company expects 2025 adjusted free cash flow to be within the range of approximately $90 million to $100 million, which includes $17 million in cash proceeds from the sale of two facilities.

    “While we navigate the uncertain demand environment, we continue to focus on our faster growing categories. Our proven ability to manage costs and generate cash flow, combined with our market-leading brands and operational excellence, gives us confidence in our long-term value creation potential,” concluded Mr. Tedford.

    Webcast

    At 8:30 a.m. ET on October 31, 2025, ACCO Brands Corporation will host a conference call to discuss the Company’s third quarter 2025 results. The call will be broadcast live via webcast. The webcast can be accessed through the Investor Relations section of www.accobrands.com. The webcast will be in listen-only mode and will be available for replay following the event.

    About ACCO Brands Corporation

    ACCO Brands is the leader in branded consumer products that enable productivity, confidence and enjoyment while working, when learning and while playing. Our widely recognized brands, include AT-A-GLANCE®, Five Star®, Kensington®, Leitz®, Mead®, PowerA®, Swingline®, Tilibra® and many others. More information about ACCO Brands Corporation (NYSE: ACCO) can be found at www.accobrands.com.

    Non-GAAP Financial Measures

    In addition to financial results reported in accordance with generally accepted accounting principles (GAAP), we have provided certain non-GAAP financial information in this earnings release to aid investors in understanding the Company’s performance. Each non-GAAP financial measure is defined and reconciled to its most directly comparable GAAP financial measure in the “About Non-GAAP Financial Measures” section of this earnings release.

    Forward-Looking Statements

    Statements contained herein, other than statements of historical fact, particularly those anticipating future financial performance, business prospects, growth, strategies, business operations and similar matters, results of operations, liquidity and financial condition, and those relating to cost reductions and anticipated pre-tax savings and restructuring costs are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the beliefs and assumptions of management based on information available to us at the time such statements are made. These statements, which are generally identifiable by the use of the words “will,” “believe,” “expect,” “intend,” “anticipate,” “estimate,” “forecast,” “future”, “project,” “plan,” and similar expressions, are subject to certain risks and uncertainties, are made as of the date hereof, and we undertake no duty or obligation to update them. Forward-looking statements are subject to the occurrence of events outside the Company’s control and actual results and the timing of events may differ materially from those suggested or implied by such forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements when deciding whether to buy, sell or hold the Company’s securities.

    Our outlook is based on certain assumptions which we believe to be reasonable under the circumstances. These include, without limitation, assumptions regarding consumer demand, tariffs, global geopolitical and economic uncertainties, and fluctuations in foreign currency exchange rates; and the other factors described below.

    Among the factors that could cause our actual results to differ materially from our forward-looking statements are: changes in trade policy and regulations, including changes in trade agreements and the imposition of tariffs, and the resulting consequences; global political and economic uncertainties; a limited number of large customers account for a significant percentage of our sales; sales of our products are affected by general economic and business conditions globally and in the countries in which we operate; risks associated with foreign currency exchange rate fluctuations; challenges related to the highly competitive business environment in which we operate; our ability to develop and market innovative products that meet consumer demands and to expand into new and adjacent product categories; our ability to successfully expand our business in emerging markets and the exposure to greater financial, operational, regulatory, compliance and other risks in such markets; the continued decline in the use of certain of our products; risks associated with seasonality, the sufficiency of investment returns on pension assets, risks related to actuarial assumptions, changes in government regulations and changes in the unfunded liabilities of a multi-employer pension plan; any impairment of our intangible assets; our ability to secure, protect and maintain our intellectual property rights, and our ability to license rights from major gaming console makers and video game publishers to support our gaming accessories business; our ability to grow profitably through acquisitions, and successfully integrate them; our ability to successfully execute our multi-year restructuring and cost savings program and realize the anticipated benefits; continued disruptions in the global supply chain; risks associated with inflation and other changes in the cost or availability of raw materials, transportation, labor, and other necessary supplies and services and the cost of finished goods; risks associated with outsourcing production of certain of our products, information technology systems and other administrative functions; the failure, inadequacy or interruption of our information technology systems or their supporting infrastructure; risks associated with a cybersecurity incident or information security breach, including that related to a disclosure of personally identifiable information; risks associated with our indebtedness, including limitations imposed by restrictive covenants, our debt service obligations, and our ability to comply with financial ratios and tests; a change in or discontinuance of our stock repurchase program or the payment of dividends; product liability claims, recalls or regulatory actions; the impact of litigation or other legal proceedings; the impact of additional tax liabilities stemming from our global operations and changes in tax laws, regulations and tax rates; our failure to comply with applicable laws, rules and regulations and self-regulatory requirements, the costs of compliance and the impact of changes in such laws; our ability to attract and retain qualified personnel; the volatility of our stock price; risks associated with circumstances outside our control, including those caused by telecommunication failures, labor strikes, power and/or water shortages, public health crises, such as the occurrence of contagious diseases, severe weather events, war, terrorism and other geopolitical incidents; and other risks and uncertainties described in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and in other reports we file with the Securities and Exchange Commission.

    View full release here.

    Christopher McGinnis
    Investor Relations
    (847) 796-4320

    Kori Reed
    Media Relations
    (224) 501-0406Source: ACCO Brands Corporation

    Release – Bitcoin Depot Schedules Third Quarter 2025 Conference Call for Thursday, November 13th at 10:00 a.m. ET

    Posted on by [email protected]

    Research News and Market Data on BTM

    October 30, 2025 4:05 PM EDT Download as PDF

    ATLANTA, Oct. 30, 2025 (GLOBE NEWSWIRE) — Bitcoin Depot (Nasdaq: BTM) (“Bitcoin Depot” or the “Company”), a U.S.-based Bitcoin ATM (“BTM”) operator and leading fintech company, will hold a conference call and live audio webcast on Thursday, November 13th at 10:00 a.m. Eastern time (7:00 a.m. Pacific time) to discuss its financial results for the third quarter ended September 30, 2025. Bitcoin Depot plans to release its results before the market opens on the same day.

    Call Date: Thursday, November 13, 2025  
    Time: 10:00 a.m. Eastern time (7:00 a.m. Pacific time)

    Phone Instructions
    U.S. and Canada (toll-free): 888-596-4144
    U.S. (toll): 646-968-2525
    Conference ID: 4229885

    Webcast Instructions
    Webcast link: https://edge.media-server.com/mmc/p/hcj2hpav/

    A replay of the call will be available beginning after 2:00 p.m. Eastern time through November 20, 2025.

    U.S. & Canada (toll-free) replay number: 800-770-2030
    U.S. toll number: 609-800-9909
    Conference ID: 4229885

    If you have any difficulty connecting with the conference call, please contact Bitcoin Depot’s investor relations team at 949-574-3860.

    About Bitcoin Depot
    Bitcoin Depot Inc. (Nasdaq: BTM) was founded in 2016 with the mission to connect those who prefer to use cash to the broader, digital financial system. Bitcoin Depot provides its users with simple, efficient and intuitive means of converting cash into Bitcoin, which users can deploy in the payments, spending and investing space. Users can convert cash to bitcoin at Bitcoin Depot kiosks in 47 states and at thousands of name-brand retail locations in 31 states through its BDCheckout product. The Company has the largest market share in North America with over 9,000 kiosk locations as of August 2025. Learn more at www.bitcoindepot.com. 

    Contacts:

    Investors 
    Cody Slach
    Gateway Group, Inc. 
    949-574-3860 
    [email protected]

    Media 
    Brenlyn Motlagh, Ryan Deloney 
    Gateway Group, Inc.
    949-574-3860 
    [email protected]

    Primary Logo

    Source: Bitcoin Depot Inc.

    Released October 30, 2025

    Release – Alliance Entertainment Secures Exclusive U.S. Home Entertainment and Digital Rights Agreement with Eli Roth’s The Horror Section

    Posted on by [email protected]

    Research News and Market Data on AENT

    PLANTATION, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) — Alliance Home Entertainment, a division of Alliance Entertainment (NASDAQ: AENT), has signed an exclusive multi-year Home Video and Digital Rights License Agreement with The Horror Section Inc., the innovative horror brand founded by acclaimed writer, director, and actor Eli Roth.

    This agreement brings together Alliance Home Entertainment’s established distribution network and The Horror Section’s innovative approach to horror content. Alliance Home Entertainment will exclusively distribute and market select horror films across physical and digital platforms in the United States.

    “I’m thrilled to be working with such an incredible, experienced team of horror lovers who truly understand the full potential of home video. I had the most amazing time working with Jeff Nelson before at Scream Factory™ and look forward to building The Horror Section with Alliance into the premiere brand of edgy, go-for-the-throat horror that I so dearly love,” said Eli Roth, Founder & Chief Creative Officer of The Horror Section.

    “We’re thrilled to partner with The Horror Section and help bring their bold, fan-first vision to life,” said Jeff Hayne, SVP Content Acquisition at Alliance Home Entertainment. “Eli Roth’s creative leadership and the studio’s commitment to redefining horror storytelling make this one of the most exciting new ventures in the genre. With a slate that blends cult appeal and breakout potential, we see enormous opportunity to connect these films with horror fans across every format and platform.”

    This partnership leverages the enthusiasm and loyalty of horror fandom, the creative leadership of Eli Roth, and Alliance Home Entertainment’s operational capabilities. The agreement is designed to support a consistent pipeline of new releases and provide investors with visibility into diversified revenue streams across physical and digital channels.

    About The Horror Section
    The Horror Section is a fan-owned 360 media company focused on building a robust library of intellectual property and creating the world’s premier horror brand. Founded by filmmaker and actor Eli Roth in partnership with Media Capital Technologies (MCT), the company spans film, television, gaming, podcasts, and live events.

    Recent projects include the newly released Jimmy and Stiggs, the upcoming Dream Eater set to debut on October 24, and Eli Roth’s latest film, Ice Cream Man, slated for 2026.

    About Alliance Home Entertainment
    Alliance Home Entertainment, a division of Alliance Entertainment (NASDAQ: AENT), is a premier licensing and distribution partner for film and television content across North America. Trusted by major Hollywood studios and leading independents alike, the division brings an expansive slate of blockbuster movies, award-winning series, and iconic library titles to market connecting premium content with fans and collectors across every major retail and digital channel.

    Alliance oversees the complete content lifecycle, offering a full suite of services including post-production, replication, creative, marketing, sales, and omnichannel distribution across physical retail, digital storefronts, and streaming platforms. With a growing emphasis on premium and collector-focused formats such as 4K Ultra HD, deluxe packaging, and exclusive editions, Alliance Home Entertainment is positioned to serve both mass-market audiences and the collector marketplace. For more information about Alliance Home Entertainment, visit https://www.alliancehomeentertainment.com.

    About Alliance Entertainment
    Alliance Entertainment (NASDAQ: AENT) is a premier distributor and fulfillment partner for the entertainment and pop culture collectibles industry. With more than 340,000 unique in-stock SKUs – including over 57,300 exclusive titles across compact discs, vinyl LPs, DVDs, Blu-rays, and video games – Alliance offers the largest selection of physical media in the market. Our vast catalog also includes licensed merchandise, toys, retro gaming products, and collectibles, serving over 35,000 retail locations and powering e-commerce fulfillment for leading retailers. The company’s growing collectibles portfolio includes Handmade by Robots™, a stylized vinyl figure line featuring licensed characters from leading entertainment franchises. Leveraging decades of operational expertise, exclusive licensing partnerships, and a capital-light, scalable infrastructure, Alliance is a trusted partner to the world’s top entertainment brands and retailers. Our omnichannel platform connects collectors and fans to the products, franchises, and experiences they love – across formats and generations. For more information, visit https://www.aent.com.

    Forward Looking Statements
    Certain statements included in this Press Release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of other financial and performance metrics and projections of market opportunity. These statements are based on various assumptions, whether identified in this Press Release, and on the current expectations of Alliance’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by an investor as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Alliance. These forward-looking statements are subject to a number of risks and uncertainties, including risks relating to the anticipated growth rates and market opportunities; changes in applicable laws or regulations; the ability of Alliance to execute its business model, including market acceptance of its systems and related services; Alliance’s reliance on a concentration of suppliers for its products and services; increases in Alliance’s costs, disruption of supply, or shortage of products and materials; Alliance’s dependence on a concentration of customers, and failure to add new customers or expand sales to Alliance’s existing customers; increased Alliance inventory and risk of obsolescence; Alliance’s significant amount of indebtedness; our ability to refinance our existing indebtedness; our ability to continue as a going concern absent access to sources of liquidity; risks and failure by Alliance to meet the covenant requirements of its revolving credit facility, including a fixed charge coverage ratio; risks that a breach of the revolving credit facility, including Alliance’s recent breach of the covenant requirements, could result in the lender declaring a default and that the full outstanding amount under the revolving credit facility could be immediately due in full, which would have severe adverse consequences for the Company; known or future litigation and regulatory enforcement risks, including the diversion of time and attention and the additional costs and demands on Alliance’s resources; Alliance’s business being adversely affected by increased inflation, higher interest rates and other adverse economic, business, and/or competitive factors; geopolitical risk and changes in applicable laws or regulations; risk that the COVID-19 pandemic, and local, state, and federal responses to addressing the pandemic may have an adverse effect on our business operations, as well as our financial condition and results of operations; substantial regulations, which are evolving, and unfavorable changes or failure by Alliance to comply with these regulations; product liability claims, which could harm Alliance’s financial condition and liquidity if Alliance is not able to successfully defend or insure against such claims; availability of additional capital to support business growth; and the inability of Alliance to develop and maintain effective internal controls.

    For investor inquiries, please contact:
    Dave Gentry
    RedChip Companies, Inc.
    1-407-644-4256
    [email protected]

    For media inquiries, please contact:
    The Horror Section
    Milly Jones
    SUBJECT
    [email protected]

    Primary Logo

    Release – Comstock Announces Third Quarter 2025 Results and Corporate Updates

    Posted on by [email protected]

    Research News and Market Data on LODE

    Fortifies Capital Base, Eliminates Debt Obligations and Funds Industry-scale Metals Launch

    VIRGINIA CITY, NEVADA, October 30, 2025 – Comstock Inc. (NYSE: LODE) (“Comstock,” “our,” and the “Company”), today announced its third quarter 2025 financial results, business updates and an updated 2025 business outlook.

    Recent Corporate Transactional and Liquidity and Capital Resources Highlights

    • Completed the oversubscribed equity raise of $34.5 million in gross proceeds ($31.8 million net of offering expenses), including overallotment, adding over 30 institutional investors to our capital base and fully funding and accelerating the commercialization of our R2v3/RIOS Responsible Recycling certified zero-landfill solar panel recycling business;
    • Eliminated all debt instruments (convertible and promissory notes) and other significant payables and obligations;
    • Placed equipment orders and paid deposits totaling $5.1 million toward the purchase of our first industry-scale solar recycling facility in Silver Springs, Nevada, capable of recycling over 3.3 million panels per year (or approximately 100,000 tons per year), and advanced activities for the next three site selections for U.S. facilities and storage capacities;  
    • Completed the purchase of the Haywood industrial mineral properties from Decommissioning Services LLC for a previously paid $2.2 million in cash and stock. The Company received cash proceeds of $0.4 million by closing the sale;
    • Executed a series of balance sheet strengthening transactions that extinguished or paid down future obligations, including those associated with acquiring AST equipment (fuels), LINICO assets, Northern Comstock mineral interests (mining), and Haywood land (mining) as well as extinguishing the Convertible Notes, Promissory Notes and other liabilities;
    • Increased net current assets to $21.3 million (current assets of $35.1 million less current liabilities of $13.8 million);
    • Cash & cash equivalents were $31.7 million as of September 30, 2025 (including $12.4 million at Bioleum Corp.); and
    • Common shares outstanding on September 30, 2025, and on October 27, 2025, were 51,264,247.

    “In January, we communicated that our progress and new states of technological readiness had positioned us for the right types of new capital to fund the growth of two extraordinary opportunities, a Nevada-based renewable metals company and an Oklahoma-based renewable oil and gas company, that, remarkably, are now funded for and rapidly moving to deploy their solutions. In all instances now, multiple, sophisticated, strategic and financial investors have made material investments in us, as we accelerate to industry-scale production,” stated Mr. Corrado De Gasperis, Executive Chairman and CEO of Comstock Inc.

    Selected Segment Highlights for Comstock Metals

    “We have ordered all of the equipment for our fully automated, industry-scale solar recycling system, and we just received affirmation on the imminent issuances of our remaining permits, on schedule, and we look forward to commissioning our first-of-its-kind, pace-setting, zero-landfill, clean solar recycling solution,” said Dr. Fortunato Villamagna, President of Comstock Metals. “We are actively engaged in the market and with our strategic customers to uniquely position ourselves for the dramatic and accelerating increases in the domestic end-of-life solar dispositions we see coming 2026, 2027, 2028, and well beyond.”

    Comstock Metals (for the nine-months ended September 30, 2025)

    • Received notice for the imminent receipt of our main operating permits for our industry-scale facility in Nevada;
    • Recorded billings of $2.9 million ($1.8 million deferred) in 2025, versus $65 thousand in the first nine months of 2024;
    • Committed to Industry-scale capital expenditures of ~$12.5 million (including expanded storage) with $5.1 million in equipment deposits paid as of September 30, 2025; and full commissioning during the first quarter of 2026;
    • Certified R2v3/RIOS Responsible Recycling Standard by Sustainable Electronics Recycling International (SERI), authenticating the first zero-waste recycling process that safely repurposes all the recycled materials;
    • Entered into a Master Services Agreement (MSA) with RWE Clean Energy (“RWE”), serving as a preferred, strategic partner for the end-of-life recycling, disposal, and decommissioning services for RWE’s solar installations; and
    • Secured three additional (this quarter) intake (tipping) master service revenue arrangements across the U.S., including industry leading customers as well as a prominent OEM for components and off-spec panels.

    “Our focus has been dedicated to continuing our business development activities to bring in panels, finalizing the site preparation, storage preparation, equipment orders and equipment supplier management, and final permits, which, based on recent meetings and review are imminent and on schedule with our overall commissioning plans,” said Comstock Metals President, Dr. Fortunato Villamagna, “while our marketing team continues to drive our message that we are the only true recycling option in the industry, and our facility planning team simultaneously coordinating strategic site selections (processing and storage) across the whole country. We remain the only certified R2v3/RIOS Responsible Recycling Standard by SERI for solar panel recycling.”

    Selected Segment Highlights for Comstock Mining (for the nine-months ended September 30, 2025)

    • Closed on the sale and monetization of the northern district claims for approximately $3 million in proceeds, including the acquisition, for no additional consideration, of more than 238 acres of Lyon County mineral properties, further enhancing our portfolio of Lyon County mineral properties and directly supporting the Dayton resource mine plans;
    • Increased our internal economic mineralized material estimates based on significantly higher gold and silver prices; and
    • Advanced the Preliminary Economic Assessment (PEA) for the Dayton with planned future publishable economics.

    In October 2025, we acquired the Haywood Quarry properties for no additional consideration, representing an additional 190 acres, further enhancing our portfolio of Lyon County mineral properties and directly supporting the Dayton plans.

    “The rapidly rising industrial silver demand and ongoing geopolitical concerns, compounded by decades of questionable monetary policy, created an unprecedented runup in gold and a possibly greater set up for silver prices over the next several years. Our historic, world-class Nevada mining assets are well positioned for expansion and monetization with sophisticated strategic and financial partners,” said Comstock’s Chief Financial Officer and Comstock Mining President, Mr. Judd Merrill.

    Selected Highlights for Bioleum Corporation (“Bioleum”) (for the nine-months ended September 30, 2025)

    • Separated our fuels portfolio and resources into the newly created, Oklahoma-headquartered Bioleum Corporation:
    • Exchanged our five-year, $65 million investment into a Series 1 Convertible Preferred Stock that is ultimately convertible into 32.5 million underlying common shares of stock of Bioleum Corporation;
    • Closed on a $13 million strategic pre-Series A investment from subsidiaries of Marathon Petroleum Corp. (“MPC”);
    • Closed on a $20 million Series A preferred equity financing, with additional Series A planned for early 2026;
    • Hired exceptional biofuel industry veterans, including a Director of Capital Markets, to accelerate commercialization;
    • Restarted the Madison, Wisconsin MPC pilot facility, expanding and fully integrating the Madison development teams;
    • Secured the first site and advanced site-specific engineering for the initially planned Oklahoma-based Bioleum refinery;
    • Earned the second $1 million of the $3 million in awards from Oklahoma’s Quick Action Closing Fund; and
    • Advanced certain strategic acquisitions that further increase yields, reduce costs, and lower carbon intensity “CI” scores.

    “Our remarkable Bioleum team has developed an unprecedented, versatile, and exceptionally high-yield, ultra-low-carbon biofuel platform that integrates waste streams and purpose-grown crops in an extending eco-system designed to produce an abundance of extremely low carbon liquid fuels,” said Corrado DeGasperis, Chairman of Board of Bioleum Corporation. “Our working teams in Wisconsin and Oklahoma are expanding as we integrate our efforts into a system designed for accelerating commercially viable technologies while integrating and expanding a series of farm-and-waste woody biomass to fuels production platforms.”

    Our goal is to Accelerate the Commercialization of Breakthrough Technologies.

    Comstock innovates and commercializes technologies, systems and supply chains that extract, integrate and convert under-utilized natural and waste resources into clean energy products, including pioneering technologies that produce electrification metals and minerals from end-of-life solar panels, including aluminum, silver and other critical metals.

    Bioleum innovates and commercializes technologies, systems and supply chains that secure, extract, integrate and convert carbon-based materials from under-utilized waste and purpose-grown energy crops that would ultimately produce a broad range of extremely low carbon renewable fuels, including cellulosic ethanol, renewable diesel and sustainable aviation fuels.

    We are pushing the boundaries of technology and sustainability by leveraging our teams’ unique skills, our investments and the related diverse technology portfolios and our frontier research and development networks toward achieving breakthrough innovations that deliver meaningful positive impact across industries, economies and communities. The primary focus for 2025 is the commercialization of Comstock Metals and the continuous innovation, development and engineering of technologies and solutions, by us and by our partners, that support the efficient conversion of these resources into clean, profitable energy products.

    Corporate 

    The growth opportunities for both Comstock Metals and Bioleum developed beyond our original plans, and we have now realigned both the organizations and their respective capital bases with some of the most sophisticated partners for investment, feedstocks, technologies, operations, and offtakes, including significant investments.

    We are expanding those partnerships across both our extended metals and fuels systems and supply chains, positioning them for industry leadership, exponential revenue growth and superior throughput profiles, especially for Metals and leading to cash profitability for Comstock Metals in 2026.

    Comstock now owns a $65 million face value convertible preferred stock in Bioleum Corporation, ultimately convertible into 32.5 million common shares of stock, positioning an exceptional value potential for Comstock’s shareholders and preserving Comstock’s ability to accelerate the growth and delivery of that value directly to shareholders.

    The Company’s Corporate remaining objectives for the rest of 2025 include:

    • Advance our legacy real estate and non-strategic investments for ultimate monetization;
    • Support the next phases of accelerating Metals growth; and
    • Finalize, communicate and implement plans to unlock maximum value from the separation of Bioleum.

    The Company’s 2025 efforts to date have now resulted in two, fully dedicated, high-growth companies: our Nevada-based renewable metals operation with expanding production and our Oklahoma-headquartered Bioleum Corporation, with major research, development and pilot production operations based in Wausau and Madison, Wisconsin.

    Comstock Metals

    Comstock Metals has now been operating its first commercial demonstration facility for nearly 21 months and in November of 2024, submitted permits for the first industry-scale photovoltaic recycling facility. The Company expects these permits to be issued imminently during the fourth quarter of 2025. The industry-scale facilities are designed for 100,000 tons of annual capacity, with operations commencing post commissioning during the second quarter 2026.

    Additional site selection activities are ongoing for the next two industry-scale facilities and multiple associated storage sites. The Company plans to ultimately build up to 7 industry-scale U.S. based recycling facilities.

    The Company’s Metals remaining objectives for the rest of 2025 include:

    • Receive final permits for our first industry-scale facility in Silver Springs, NV;
    • Procure, deploy, and assemble plant and equipment for our first industry-scale facility in Silver Springs, NV;
    • Secure additional Master Service Agreements (MSA) with national and regional customers;
    • Complete site selection for two additional solar panel recycling locations;
    • Expand the system globally with international strategic and capital partners; and
    • Advance R&D efforts to recover more and higher-purity materials from recycled streams for offtake.

    The capital expenditures for the first 100,000 tons of annual capacity for the first industry scale facility are expected to be approximately $12.5 million which includes expanded storage. As of September 30, 2025, the Company paid deposits of $5.1 million for property, plant and equipment and anticipates a total capital spend of $10.0 million for the industry-scale by the end of 2025, with an additional $2-3 million expected in the first quarter of 2026. Billable revenues are expected to be eight times greater in 2025, as compared to 2024, or over $3.5 million, with proportionate 2026 increases as we scale up our facility. 

    Comstock Mining

    Comstock Mining has amassed the single largest known repository of historical and current geological data within the Comstock mineral district, including extensive geophysical surveys, geological mapping, and drilling data, including the Dayton resource.

    The Company’s Mining remaining objectives for the rest of 2025 include:

    • Commercialize agreements that either monetize or enable resource expansion of the central claims;
    • Publish the Dayton Consolidated Project technical work with preliminary economics and sensitivities; and
    • Complete the preliminary mine plans that enable the economic development of the southern district claims.

    The Company’s 2025 efforts will apply economic analysis to Comstock’s existing gold and silver resources progressing toward preliminary economic feasibility for the southern part of the district and the ultimate development of full mine and reclamation plans and the development of post productive land and community development plans.

    Bioleum

    Bioleum is actively engaged in the expansion of its pilot production facilities and the planning for its first commercial demonstration facilities and the associated supply chain participants (including feedstock, site selection, engineering, construction and procurement, and offtake).

    Bioleum’s remaining objectives for the rest of 2025 include:

    • Commercialize agreements that either monetize or enable resource expansion of the central claims;
    • Advance efforts on the remaining subsidiary level “Series A” equity financing in the separate Fuels entity;
    • Plan and deploy a Hexas-based, scalable, commercial demonstration fuel farm
    • Complete site selection for first commercial biorefinery project in Oklahoma;
    • Expand integrated pilot production capabilities to up to two barrels per week of intermediates and fuels; and
    • Advance our innovation and development efforts toward even higher yields, lower costs and lower capital.

    Comstock Fuels also offers integrations of its solutions into existing agriculture, forestry, pulp and paper, ethanol, and existing petroleum infrastructures to generate additional capacities, revenues, technical services, engineering and royalties. The plans also include integrating Bioleum’s high yield Bioleum refining platform with Hexas’ high yield energy crops to provide enough feedstock to produce upwards of 100 barrels of fuel per acre per year, effectively transforming agricultural lands into perpetual “drop-in sedimentary oilfields” with the potential to dramatically boost domestic energy resources.

    CONFERENCE CALL DETAILS

    Comstock’s Executive Chairman & CEO, Corrado De Gasperis, and CFO, Judd Merrill will be providing an overview of recent financial results and current business updates on Thursday, October 30, 2025, at 11:30am ET. We invite all investors and other interested parties to register for the webinar at the link below.

    Date: Thursday, October 30, 2025
    Time: 11:30am ET
    Register: Webinar Registration

    There will be an allotted time following the live presentation for a Q&A session. Unaddressed questions will be reviewed by management and responded to accordingly. You may submit your question(s) beforehand in the registration form (linked above) or by email at: [email protected].

    About Comstock Inc.

    Comstock Inc. (NYSE: LODE) innovates and commercializes technologies, systems and supply chains that enable, support and sustain clean energy systems by efficiently, effectively, and expediently extracting and converting under-utilized natural resources into reusable metals, like silver, aluminum, gold, and other critical minerals, primarily from end-of-life photovoltaics. To learn more, please visit www.comstock.inc.

    Comstock Social Media Policy

    Comstock Inc. has used, and intends to continue using, its investor relations link and main website at www.comstock.inc in addition to its X.com, LinkedIn and YouTube accounts, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

    Contacts

    For investor inquiries:
    Judd B. Merrill, Chief Financial Officer
    Tel (775) 413-6222
    [email protected]

    For media inquiries:
    Zach Spencer, Director of External Relations
    Tel (775) 847-7573
    [email protected]

    Forward-Looking Statements 

    This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future market conditions; future explorations or acquisitions; divestitures, spin-offs or similar distribution transactions, future changes in our research, development and exploration activities; future financial, natural, and social gains; future prices and sales of, and demand for, our products and services; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land and asset sales; investments, acquisitions, divestitures, spin-offs or similar distribution transactions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; business opportunities, growth rates, future working capital, needs, revenues, variable costs, throughput rates, operating expenses, debt levels, cash flows, margins, taxes and earnings. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments, and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration, metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious and other metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; challenges to, or potential inability to, achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology and efficacy, quantum computing and generative artificial intelligence supported advanced materials development, development of cellulosic technology in bio-fuels and related material production; commercialization of cellulosic technology in bio-fuels and generative artificial intelligence development services; ability to successfully identify, finance, complete and integrate acquisitions, spin-offs or similar distribution transactions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund, or any other issuer.

    Release – SEGG Media Charts a Bold Course into Web3 with $300M Digital Asset Initiative

    Posted on by [email protected]

    Research News and Market Data on SEGG

    October 30, 2025

    PDF Version

    FORT WORTH, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) — SEGG Media Corporation (Nasdaq: SEGG, LTRYW) (“SEGG Media” or “the Company”) today announced the launch of its Web3 and Digital Asset Strategy, a two-year roadmap to generate sustainable on-chain yield, accelerate tokenization across sports and entertainment, and embed blockchain infrastructure into its global media ecosystem.

    The initiative follows the creation of the SEGG Media Crypto Advisory Board, which is being established to provide guidance for governance, risk management, and execution of the Company’s $300 million Digital Asset and Tokenization Program. This strategy positions SEGG Media among the first NASDAQ-listed companies to bridge traditional finance, sports entertainment, and blockchain-based revenue streams within a regulated framework.

    Reimagining Growth Through Active Digital Asset Management

    At the core of SEGG’s roadmap lies an 80/20 capital allocation model designed to balance stability, yield, and growth:

    • 80% of deployed capital will be maintained as a multi-asset crypto treasury, with an initial emphasis on Bitcoin (BTC) given current market sentiment and institutional demand, generating validator-based income across Ethereum (ETH), Solana (SOL), and ZIGChain (ZIG).
    • 20% will fund strategic acquisitions in sports, media, and gaming, expanding the Company’s recurring-revenue base, as well as expansion into tokenization of real-world sports assets & other Web3 capabilities to democratize retail investor participation.

    SEGG Media also signed an MOU outlining the framework for strategic partnership with ZIGChain, a purpose-built blockchain for real-world asset tokenization. ZIGChain provides the technological infrastructure and digital investment expertise for the Company’s validator operations and tokenized asset programs.

    This model aims to create recurring on-chain yield as the Company scales into a next-generation digital media and entertainment group. All income resulting from validator activities will be reported through SEC-compliant filings to ensure transparency and measurable shareholder value.

    Beyond Passive Holdings: Building the Future of Sports and Entertainment Tokenization

    SEGG Media’s Web3 roadmap goes beyond holding digital assets. Anchored by Sports.com and Concerts.com, the Company plans to develop a fully tokenized sports and entertainment ecosystem built on four core pillars:

    1. Digital Asset Treasury & Validator Yield – Sustainable, yield-generating multi-crypto operations.
    2. Sports and Entertainment Tokenization Ecosystem – Tokenized assets enabling fan ownership, athlete and artist IP monetization, and global engagement via ZIGChain.
    3. Sports and Entertainment Exchange Initiative – The world’s first “Stock Exchange for Sports and Music Lovers,” allowing fans to trade tokenized sports teams and bands or artists.
    4. Strategic Acquisitions – Deployment of validator income into cash-generative assets across sports, entertainment media, and gaming.

    Execution Roadmap

    The Company will execute the rollout through four phases:

    • Phase 1 (0–1 months): SEGG Media Crypto Advisory Board activation, validator setup, and treasury seeding.
    • Phase 2 (0–6 months): Tokenization pilots under Sports.com and Concerts.com with ZIGChain; integration of income from validator activities into corporate filings.
    • Phase 3 (0–12 months): Expansion of the Sports and Entertainment Exchange platform and launch of tokenized fan assets.
    • Phase 4 (12–18 months): Full Web3 convergence—multi-asset treasury, active validators, and tokenized revenue stack.

    Leadership Commentary

    “Our mission is to responsibly connect traditional markets with blockchain innovation,” said Matthew McGahan, Chairman, President & CEO of SEGG Media. “By emphasizing Bitcoin as the foundation of our treasury, we’re combining stability with scalability—using validator income to fuel growth, and growth to accelerate tokenization across our global media ecosystem.”

    “Entering into an MOU with SEGG Media represents a milestone for blockchain adoption at the public-company level,” said Abdul Rafay Gadit, Founder of ZIGChain. “By leveraging ZIGChain’s real-world asset tokenization framework, SEGG Media is pioneering how institutional-grade infrastructure can power yield, transparency, and fan participation on a global scale.”

    Marc Bircham, Director of SEGG Media added: “This strategy unites sports, technology, and digital finance within a regulated, scalable framework. It’s a blueprint for how listed companies can responsibly adopt Web3 while building lasting value for investors and fans alike.”

    Governance and Transparency

    The SEGG Media Crypto Advisory Board will provide guidance to SEGG’s Executive Management and Board of Directors on all treasury, validator, and tokenization operations, safeguarding institutional-grade governance and transparency.

    About SEGG Media Corporation
    SEGG Media (Nasdaq: SEGG, LTRYW) is a global sports, entertainment and gaming group integrating traditional assets with blockchain innovation. Through its portfolio of digital assets including Sports.com, Concerts.com and Lottery.com, the Company is focused on building immersive fan engagement, ethical gaming and AI-driven live experiences, SEGG Media is redefining how global audiences interact with the content they love.

    About ZIGChain

    ZIGChain is a next-generation blockchain infrastructure designed for real-world asset (RWA) tokenization. Built for scalability, compliance, and composability, ZIGChain enables institutions to tokenize and trade traditionally illiquid assets securely and transparently. Through partnerships across finance, entertainment, and digital infrastructure, ZIGChain is redefining how real-world value is represented and exchanged on-chain.

    For more information, visit www.zigchain.com.

    Important Notice Regarding Forward-Looking Statements

    This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this press release, regarding the Company’s strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. When used in this Form 8-K, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” “initiatives,” “continue,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. The forward-looking statements speak only as of the date of this press release or as of the date they are made. The Company cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company. In addition, the Company cautions you that the forward-looking statements contained in this press release are subject to risks and uncertainties, including but not limited to, any future findings from ongoing review of the Company’s internal accounting controls, additional examination of the preliminary conclusions of such review, the Company’s ability to secure additional capital resources, the Company’s ability to continue as a going concern, the Company’s ability to respond in a timely and satisfactory matter to the inquiries by Nasdaq, the Company’s ability to regain compliance with the Bid Price Requirement, the Company’s ability to regain compliance with Nasdaq Listing Rules, the Company’s ability to become current with its SEC reports, and those additional risks and uncertainties discussed under the heading “Risk Factors” in the Form 10-K/A filed by the Company with the SEC on April 22, 2025, and the other documents filed, or to be filed, by the Company with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that the Company has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC’s website at www.sec.gov. Should one or more of the risks or uncertainties described in this press release materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release.

    This press release was published by a CLEAR® Verified individual.

    For additional information, visit www.seggmediacorp.com or contact media relations at [email protected].